Amino Acids

, Volume 41, Issue 5, pp 1103–1112

Phage display peptide probes for imaging early response to bevacizumab treatment

  • Qizhen Cao
  • Shuanglong Liu
  • Gang Niu
  • Kai Chen
  • Yongjun Yan
  • Zhaofei Liu
  • Xiaoyuan Chen
Original Article


Early evaluation of cancer response to a therapeutic regimen can help increase the effectiveness of treatment schemes and, by enabling early termination of ineffective treatments, minimize toxicity, and reduce expenses. Biomarkers that provide early indication of tumor therapy response are urgently needed. Solid tumors require blood vessels for growth, and new anti-angiogenic agents can act by preventing the development of a suitable blood supply to sustain tumor growth. The purpose of this study is to develop a class of novel molecular imaging probes that will predict tumor early response to an anti-angiogenic regimen with the humanized vascular endothelial growth factor antibody bevacizumab. Using a bevacizumab-sensitive LS174T colorectal cancer model and a 12-mer bacteriophage (phage) display peptide library, a bevacizumab-responsive peptide (BRP) was identified after six rounds of biopanning and tested in vitro and in vivo. This 12-mer peptide was metabolically stable and had low toxicity to both endothelial cells and tumor cells. Near-infrared dye IRDye800-labeled BRP phage showed strong binding to bevacizumab-treated tumors, but not to untreated control LS174T tumors. In addition, both IRDye800- and 18F-labeled BRP peptide had significantly higher uptake in tumors treated with bevacizumab than in controls treated with phosphate-buffered saline. Ex vivo histopathology confirmed the specificity of the BRP peptide to bevacizumab-treated tumor vasculature. In summary, a novel 12-mer peptide BRP selected using phage display techniques allowed non-invasive visualization of early responses to anti-angiogenic treatment. Suitably labeled BRP peptide may be potentially useful pre-clinically and clinically for monitoring treatment response.


Phage display Angiogenesis Therapy response Bevacizumab Molecular imaging 

Supplementary material

726_2010_548_MOESM1_ESM.doc (3.4 mb)
Supplementary figures (DOC 3,513 kb)


  1. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380PubMedCrossRefGoogle Scholar
  2. Augustin HG, Kozian DH, Johnson RC (1994) Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 16:901–906PubMedCrossRefGoogle Scholar
  3. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker RA, Woodcock J, Zeger SL (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRefGoogle Scholar
  4. Borsum T, Hagen I, Henriksen T, Carlander B (1982) Alterations in the protein composition and surface structure of human endothelial cells during growth in primary culture. Atherosclerosis 44:367–378PubMedCrossRefGoogle Scholar
  5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMedGoogle Scholar
  6. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRefGoogle Scholar
  7. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB (2002) Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8:3226–3231PubMedGoogle Scholar
  8. Fujio Y, Walsh K (1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274:16349–16354PubMedCrossRefGoogle Scholar
  9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S–93SPubMedGoogle Scholar
  10. Hallahan D, Geng L, Qu S, Scarfone C, Giorgio T, Donnelly E, Gao X, Clanton J (2003) Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3:63–74PubMedCrossRefGoogle Scholar
  11. Han Z, Fu A, Wang H, Diaz R, Geng L, Onishko H, Hallahan DE (2008) Noninvasive assessment of cancer response to therapy. Nat Med 14:343–349PubMedCrossRefGoogle Scholar
  12. Hardy B, Raiter A, Weiss C, Kaplan B, Tenenbaum A, Battler A (2007) Angiogenesis induced by novel peptides selected from a phage display library by screening human vascular endothelial cells under different physiological conditions. Peptides 28:691–701PubMedCrossRefGoogle Scholar
  13. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 94:883–893PubMedGoogle Scholar
  14. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998PubMedCrossRefGoogle Scholar
  15. Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, Chen X (2006) In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol 8:315–323PubMedCrossRefGoogle Scholar
  16. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB (2002) Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161:1917–1924PubMedCrossRefGoogle Scholar
  17. Hughes MS, Marsh JN, Zhang H, Woodson AK, Allen JS, Lacy EK, Carradine C, Lanza GM, Wickline SA (2006) Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo. IEEE Trans Ultrason Ferroelectr Freq Control 53:1609–1616PubMedCrossRefGoogle Scholar
  18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  19. Jaffe CC (2006) Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245–3251PubMedCrossRefGoogle Scholar
  20. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4:655–657PubMedCrossRefGoogle Scholar
  21. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989PubMedCrossRefGoogle Scholar
  22. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
  23. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24–40PubMedCrossRefGoogle Scholar
  24. Kelly KA, Waterman P, Weissleder R (2006) In vivo imaging of molecularly targeted phage. Neoplasia 8:1011–1018PubMedCrossRefGoogle Scholar
  25. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171–1175PubMedCrossRefGoogle Scholar
  26. Li ZB, Wu Z, Chen K, Ryu EK, Chen X (2008) 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 49:453–461PubMedCrossRefGoogle Scholar
  27. Liu Z, Yan Y, Chin FT, Wang F, Chen X (2009) Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using (18)F-labeled PEGylated RGD-bombesin heterodimer (18)F-FB-PEG(3)-Glu-RGD-BBN. J Med Chem 52:425–432PubMedCrossRefGoogle Scholar
  28. Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, Badve S, Storniolo A, Goulet R, Sledge GW Jr (2005) Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 89:187–197PubMedCrossRefGoogle Scholar
  29. Padhani AR (2003) MRI for assessing antivascular cancer treatments. Br J Radiol 76(Spec No. 1):S60–S80PubMedCrossRefGoogle Scholar
  30. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364–366PubMedCrossRefGoogle Scholar
  31. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430–437PubMedCrossRefGoogle Scholar
  32. Seung-Min L, Gil-Suk Y, Eun-Sang Y, Tae-Gyun K, In-San K, Byung-Heon L (2009) Application of phage display to discovery of tumor-specific homing peptides: developing strategies for therapy and molecular imaging of cancer. Methods Mol Biol 512:355–363PubMedCrossRefGoogle Scholar
  33. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369–3372PubMedGoogle Scholar
  34. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731–3736PubMedCrossRefGoogle Scholar
  35. Tozer GM (2003) Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 76(Spec No. 1):S23–S35PubMedCrossRefGoogle Scholar
  36. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147PubMedCrossRefGoogle Scholar
  37. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMedGoogle Scholar
  38. Wu Y, Cai W, Chen X (2006) Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol 8:226–236PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Qizhen Cao
    • 1
  • Shuanglong Liu
    • 1
  • Gang Niu
    • 2
  • Kai Chen
    • 2
  • Yongjun Yan
    • 2
  • Zhaofei Liu
    • 1
  • Xiaoyuan Chen
    • 1
    • 2
  1. 1.Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X ProgramStanford University School of MedicineStanfordUSA
  2. 2.Laboratory of Molecular Imaging and Nanomedicine (LOMIN)National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)BethesdaUSA

Personalised recommendations